Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids-Reference-Cited by-同舟云学术

Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids

Published:2023-09-11 Issue:6 Volume:24 Page:913-925
ISSN:1175-0561
Container-title:American Journal of Clinical Dermatology
language:en
Short-container-title:Am J Clin Dermatol

Author:

Silverberg Jonathan I.^ORCID,Armstrong April^ORCID,Blauvelt Andrew^ORCID,Reich Kristian^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40257-023-00809-0.pdf

Reference36 articles.

1. Vilsbøll AW, Anderson P, Piercy J, Milligan G, Kragh N. Extent and impact of inadequate disease control in US adults with a history of moderate to severe atopic dermatitis following introduction of new treatments. Dermatol Ther (Heidelb). 2021;11(2):475–86.

2. Puar N, Chovatiya R, Paller AS. New treatments in atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):21–31.

3. DUPIXENT (dupilumab) [package insert]. New York: Regeneron; 2017.

4. ADBRY (tralokinumab) [package insert]. New Jersey: LEO Pharma; 2021.

5. CIBINQO (abrocitinib) [package insert]. New York: Pfizer; 2022.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological Trends in the Management of Atopic Dermatitis: A Comprehensive Review;Cureus;2024-07-11

2. Pearls for practice from the 2023 allergy immunology joint task force on practice parameters GRADE and institute of medicine based atopic dermatitis guidelines;Current Opinion in Pediatrics;2024-06-19

3. Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis;Dermatology and Therapy;2024-04

4. Patients’ preferences for systemic treatment of atopic dermatitis: safety and efficacy count the most;Journal of Dermatological Treatment;2024-01-31